Instructions for Detralex (Diosmin) [Phlebodia 600]
Release Form [Phlebodia 600]:
tab., film cover, 500 mg: 28, 30, 36, 56 or 60 pcs.
Pills covered with film wrapped orange-pink color, oval;
The appearance of the pill on the fracture - from pale yellow to yellow color of the heterogeneous structure.
500 mg purified micronized flavonoid fraction,
including diosmin 450 mg (90%)
Fluvonoids per Hesperidine of 50 mg (10%)
Auxiliary substances: gelatin - 31 mg, magnesium staarat - 4 mg, cellulose microcrystalline - 62 mg, carboxymethyl starchmal sodium - 27 mg, talc - 6 mg, water purified - 20 mg.
Composition of the membrane:
Macrogol 6000 - 0.710 mg, sodium lauryl sulfate - 0.033 mg, premix for the film shell orange-pink color (glycerol - 0.415 mg, magnesium Stearat - 0.415 mg, hypromellosis - 6.886 mg, iron dye oxide yellow - 0.161 mg, iron dye oxide red - 0.054 mg, titanium dioxide - 1.326 mg).
12 pcs. - Blister (3) - cardboard packs, with the control of the first autopsy (if necessary).
14 pcs. - Blister (2) - cardboard packs, with the control of the first autopsy (if necessary).
14 pcs. - Blister (4) - packs of cardboard, with the control of the first autopsy (if necessary).
15 pcs. - Blister (2) - cardboard packs, with the control of the first autopsy (if necessary).
15 pcs. - Blister (4) - packs of cardboard, with the control of the first autopsy (if necessary).
ATX codes [Phlebodia 600]
C05CA53 Diosmin in combination with other drugs Detralex
Pharmacological groups / Group membership
Ventonizing and venotrektor drug Detralex
purified micronized flavonoid fraction
Pharmacy Group [Phlebodia 600]:
Ventonizing and venotrektor
The drug should be stored in a place not accessible to children at a temperature not exceeding 30°C.
Shelf life - 4 years. Do not apply after expiry date specified on the package.
Detralex has venotonizing and angioprotector properties. The drug reduces the stretch of veins and venous stagnation, reduces the permeability of capillaries and increases their resistance. The results of clinical trials confirm the pharmacological activity of the drug Detralex with regard to the venous hemodynamics indicators.
The statistically reliable dose-dependent effect of Detralex was demonstrated for the following venous plethysmographic parameters: venous capacitance, venous stretching, venous emptying time.
The optimal dose-effect ratio is observed when taking 2 tablets.
Detralex raises the venous tone: With the help of venous occlusionic plasmography, the time of venous emptying was reduced. Patients with signs of a marked microcirculation disorder after the treatment of Detralex (statistically reliable, as compared to placebo) increase of capillary resistance, estimated by the method of angiostereometry.
Therapeutic effectiveness of Detralex drug Detralex in the treatment of chronic diseases of the veins of the lower limbs, as well as in the treatment of hemorrhoids.
Detralex is shown for therapy of symptoms of chronic veins diseases (elimination and relief of symptoms).
The therapy of symptoms of venous-lymphatic insufficiency:
lower limb cramps;
a sense of gravity and slack in the legs;
"fatigue" of the legs.
Therapy of venous-lymphatic insufficiency
The edema of the lower limbs
trophic changes in skin and subcutaneous fiber
venous trophic ulcers.
Symptomatic therapy of acute and chronic hemorrhoids.
Method of application, course and dosage [Phlebodia 600]:
The drug Detralex is administered inside. Pills should be swallowed entirely by drinking water.
Recommended dose for venous lymphatic insufficiency - 2 tab/day (for 1 or 2 intake): morning, afternoon and/or evening, while eating.
The duration of the course of treatment may be several months (up to 12 months). In case of repeated symptoms, the treatment may be repeated on the recommendation of the doctor.
The recommended dose for acute hemorrhoids is 6 tab/day (3 tab. in the morning and 3 tab. in the evening) for 4 days, followed by 4 tab/day (2 tab. in the morning and 2 tab. in the evening) for the following 3 days .
The recommended dose for chronic hemorrhoids is 2 tab./day with meal.
No overdose was reported.
If the drug Detralexis overdose, the patient must immediately seek medical treatment.
Drug Interaction [Phlebodia 600]:
There were no clinical studies on the interaction of Detralex with other drugs
To date, no cases of drug Detralex interaction have been reported.